Bob Mauch

In the medium to long term, I'm confident that we will because we'll make the right infrastructure investments and capability investments to make sure that we can do that.

So we're really excited about it.

I think logistics change, right?

So right now, even the most

complex, you know, biologic specialty therapies, they still are going to come from a manufacturer warehouse, you know, into one of our warehouses.

Now it's a different warehouse, different capabilities, a cold chain, obviously, but it's still something that we would, you know, buy from the manufacturer.

We would take title to it and then we would warehouse it.

And then just in time, get that to a provider, to a patient bedside.

I think as you get to more

personalized therapies.

So just, you know, cell therapy or gene therapy.

The part of the process where it goes to a warehouse and sits there for some period of time, that goes away.

But the logistics and the orchestration is actually still there.

So if you think about, you know, a cell therapy that is going to begin with a patient.

So we're going to take cells from that patient and then the cells are going to get to a lab.

and then they're going to be processed, and then they're going to go back to the patient.

Well, all of that has to be orchestrated.

So there's a really precise timing there.

There's a role for us in that, and we have capabilities and technology that helps with that.

And then it's also that highest end of distribution or logistics.